All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
After receiving haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) some patients may also receive posttransplant cyclophosphamide (PTCy) as a graft-versus-host disease (GvHD) prophylaxis. However, it remains uncertain how patients who receive haplo-PBSCT and PTCy are impacted by CD34+ cell dose from their donor graft.
Here, we summarize an article by Maruyama et al.1 published in Blood Cells, Molecules and Diseases evaluating how CD34+ cell dose impacts patient outcomes after haplo-PBSCT with PTCy treatment.
Figure 1. Survival outcomes at 3 years after haplo-PBSCT*
GRFS, graft-versus-host disease-free relapse-free survival; haplo-PBSCT, haploidentical peripheral blood stem cell transplantation; OS, overall survival; PFS, progression-free survival.
*Data from Maruyama, et al.1
Table 1. Outcomes of both groups after haplo-PBSCT*
|
Haplo-low |
Haplo-high |
p value |
---|---|---|---|
Median time to achieve an absolute neutrophil count of ≥0.5 × 109/L |
17 days |
17 days |
p = 0.832 |
Median time to achieve a platelet count of ≥50 × 109/L |
33 days |
29 days |
p = 0.466 |
NRM (95% CI), % |
0.0 |
19 |
p = 0.075 |
Cumulative incidence of Grade 2-4 aGvHD (95% Cl), % |
40.0 |
16.7 |
p = 0.058 |
Cumulative incidence of moderate-to-severe cGvHD (95% CI), % |
13.3 |
17.6 |
p = 0.720 |
aGvHD, acute graft-versus-host disease; cGvHD, chronic graft-versus-host disease; CI, confidence interval; haplo-PBSCT, haploidentical peripheral blood stem cell transplantation; NRM, non-relapse mortality. |
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox